Ester-Modified Radioactive Compound for Pancreatic Cancer Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tumor contrast agents face challenges in achieving high tumor-to-background ratios due to high uptake in organs like the liver and spleen, limiting their effectiveness in diagnostic imaging, especially for pancreatic cancer, which is difficult to diagnose early.
Innovation Solution
A novel radioactive compound with an ester group is developed, utilizing differential esterase activity between tumors and MPS organs, formulated into liposomes with a specific lipid composition to enhance tumor uptake and reduce background noise, allowing for improved visualization of pancreatic cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional contrast agents are used for tumor imaging, then tumor visualization is achieved, but background noise from MPS organs (liver and spleen) limits the tumor-to-background ratio
Solution Approach 1:
The patent changes the chemical parameter by introducing an ester group into the contrast agent molecule. This modification enables the agent to be selectively hydrolyzed by high esterase activity in tumors, causing retention at the tumor site while being cleared from MPS organs with low esterase activity, thereby improving the tumor-to-background ratio
Solution Approach 2:
The ester group acts as an intermediary mechanism that mediates differential retention between tumors and MPS organs. The ester bond serves as a chemical intermediary that is selectively cleaved by esterase enzymes, enabling the contrast agent to differentiate between tumor tissue and background organs based on enzymatic activity differences
2Object-affected harmful factors
If nanoparticle size is reduced to 5 nm or less for rapid renal clearance, then background noise is reduced, but blood circulation time is insufficient for high tumor uptake
Solution Approach 1:
Instead of changing the physical parameter of nanoparticle size, the patent changes the chemical parameter by incorporating an ester group that enables enzymatic cleavage. This allows the contrast agent to maintain sufficient circulation time while achieving selective tumor retention through differential esterase activity, avoiding the need for ultra-small nanoparticle sizes
3Measurement precision
If pre-targeting imaging strategies or clearance agents are used to reduce background noise, then tumor-to-background ratio improves, but the requirement for challenging chemicals and second injection limits clinical application
Solution Approach 1:
The patent extracts the complexity from the imaging protocol by incorporating the ester group directly into the contrast agent molecule itself. This eliminates the need for separate pre-targeting agents or clearance agents, allowing selective tumor imaging to be achieved through a single injection of the modified contrast agent
Solution Approach 2:
The ester-containing contrast agent performs multiple functions: it serves as both the imaging agent and the selective targeting mechanism. The ester group enables the single molecule to achieve both circulation and selective tumor retention, eliminating the need for separate targeting and imaging components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound achieves significant tumor-to-organ uptake ratios and accumulation in tumors, providing clear imaging with reduced background noise, facilitating early detection of pancreatic cancer.
Implementation Method 1
utilizing the activity of esterase differentially expressed in tumors and MPS organs
Implementation Method 2
the activity of esterase differentially expressed in tumors and MPS organs
Implementation Method 3
X is a diagnostically active radioisotope selected from the group consisting of 43Sc, 44Sc, 51Mn, 52Mn, 64Cu, 67Ga, 68Ga, 86Y 89Zr, 94mTc, 99mTc, 111In 152Tb, 155Tb, 201Tl, 203Pb, 18F, 76Br, 77Br, 123I, 124I and 125I
Data Source
AI summary
The present invention relates to a novel compound comprising an ester group and uses thereof and, more particularly, to a novel compound that exhibits excellent visualization ability in a tumor by using the difference in activity of esterase for each organ in the body, and to uses therefor for diagnosing or treating cancer. A novel compound of chemical Formulas 1 to 8 according to the present invention exhibits selectivity according to the difference in activity of esterase for each organ due to ester residue in a structure, and thus is extremely effective in visualizing pancreatic cancer, etc.